Daily Chart

Send a Tweet

$NVS
#Novartis Ag-adr
NVS
Novartis Ag-adr
Look for:
NVS
Pre-Market Movers: $NVO,$FCL,$PCZ,$GSK,$ERTS,$HBC,$DDR,$DB,$GFA,$NVS...more
NVS
Novartis $NVS in-licenses a mid-to-late-stage experimental hepatitis C drug from a private Swiss co. Gains exclusive WW rights,except Japan.
NVS
Monday February 8 2010 MACD Sell Signal $ALXN $BAP $GILD $MCD $ROST $NVS $PETD $PII $LKFN $NTY #economics
NVS
@drpdtapp yes $NVS have Afinitor and $GSK have pazopanib. There are 6 approved in renal cc now
NVS
Getting ready for exclusive interview w/Roche CEO Severin Schwan @ 7:30a ET-ish on Squawk Box. $RHHBY $NVS (@mhuckman)
NVS
Getting ready for exclusive interview w/Roche CEO Severin Schwan @ 7:30a ET-ish on Squawk Box. Crew tweaking lights now. $RHHBY $NVS
NVS
Allergan’s Looking Real Pretty Right Now http://cnbc.com/id/35238576 $ABT $ACL $AGN $NVS #StockPicks #StockMarket
NVS
RT@MhuckmanRoche CEO Severin Schwan live 2mrw @ 7:30a ET-ish on "Squawk Box." 1st CNBC U.S. interview since buying Genentech. $RHH
NVS
Roche CEO Severin Schwan live 2mrw @ 7:30a ET-ish on "Squawk Box." 1st CNBC U.S. interview since buying Genentech. $RHHBY $NVS
NVS
Pfizer Earnings By the Numbers http://cnbc.com/id/35196988 $AMGN $BIIB $GENZ $GILD $MRK $NVS $PFE $WAT #StockMarket
NVS
$NVS $CSBTF Hypertension Market Will Be Constrained Through 2018 by Pipeline Containing Few Novel Emerging Therapies http://bit.ly/c3boXR
NVS
Is Genentech/Roche turning a blind eye to a marketing/PR opportunity for Lucentis/Avastin? Vote in the poll. http://bit.ly/9VSjxq $NVS
NVS
RT @adamfeuerstein: @mhuckman: Kaiser "real-world" study:Avastin = Lucentis for AMD. $NVS $RHHBY Genentech: Only L proven safe,eff
NVS
RT @mhuckman: BREAKING Kaiser "real-world" study:Avastin works just as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucent
NVS
RT @mhuckman: Kaiser "real-world" study:Avastin works as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucentis proven safe
NVS
RT @mhuckman: BREAKING Kaiser "real-world" study:Avastin works just as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucent
NVS
BREAKING Kaiser "real-world" study:Avastin works just as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucentis proven safe
NVS
RT @mhuckman: FDA OKs using Glaxo's Tykerb w/Novartis' Femara for certain type advanced breast cancer in post-menopausal women. $GSK $NVS.
NVS
RT @mhuckman: FDA OKs using Glaxo's Tykerb w/Novartis' Femara for certain type advanced breast cancer in post-menopausal women. $GSK $NVS.
NVS
FDA OKs using Glaxo's Tykerb w/Novartis' Femara for certain type advanced breast cancer in post-menopausal women. $GSK $NVS.




Novartis Ag-adr - NVS Insiders

No Insiders

We have no insiders for Novartis Ag-adr right now.

Know someone who is an insider on Novartis Ag-adr?
Let us know.

Novartis Ag-adr - NVS information

...
133,000 Employees
Last Reported Date: 10/28/14
Founded in 1895
Last $92.69 USD
Change Today +0.74 / 0.80%
Volume 967.0K
As of 8:04 PM 10/31/14 All times are local (Market data is delayed by at least 15 minutes).

novartis ag-adr (NVS) Snapshot

Open
$92.42
Previous Close
$91.95
Day High
$92.93
Day Low
$92.24
52 Week High
09/17/14 - $95.50
52 Week Low
11/8/13 - $76.36
Market Cap
250.8B
Average Volume 10 Days
1.2M
EPS TTM
--
Shares Outstanding
2.7B
EX-Date
02/27/14
P/E TM
--
Dividend
$2.76
Dividend Yield
2.98%
Request Investor Kit
NVS:US Advanced Stock Chart

novartis ag-adr (NVS) Related Bloomberg News

Actavis Blood Pressure Pill Not Backed by U.S. Advisers
Amazon, Oracle, Toshiba, Cipla: Intellectual Property
Fed Taper Question Keeps U.S. Corporate Bond Sales Below Average
Novartis Jury Awards $10.45 Million for Drug, Lawyer Says
Novartis’s Alcon Wins Bid to Block Apotex’s Generic Patanol

novartis ag-adr (NVS) Related News

Australia's CSL Wants to Make Your Flu Shots
Botox Maker Plans Deep Job Cuts During Takeover Fight
Who Should Pay the Bill for Wonder Drugs?
Big Pharma's Favorite Prescription: Higher Prices
[addPosition2]

novartis ag-adr (NVS) Key Developments

Novartis to Invest USD 220 Million in Facilities and R&D in Mexico

Novartis announced it will invest USD 220 million in facilities and research and development (R&D) in Mexico. The company will spend USD 150 million in its Mexican facilities and USD 20 million in a quality assessment centre during 2015. Additionally, in five years, more than USD 50 million will be invested in Novartis's R&D in Mexico.

Novartis AG Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Sales Guidance for the Full Year 2014

Novartis AG reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net sales to third parties from continuing operations of USD 12,991 million against USD 12,705 million a year ago. Net sales of segments from continuing operations were USD 13,046 million against USD 12,574 million a year ago. Operating income from continuing operations were USD 2,739 million against USD 2,558 million a year ago. Income before taxes from continuing operations were USD 3,532 million against USD 2,488 million a year ago. Net income from continuing operations was USD 3,102 million or USD 1.25 per diluted share against USD 2,159 million or USD 0.86 per diluted share a year ago. Total net income attributable to shareholders of the company was USD 3,223 million or USD 1.31 per diluted share against USD 2,232 million or USD 0.90 per diluted share a year ago. Total cash flows from operating activities were USD 4,011 million against USD 4,379 million a year ago. Purchase of property, plant & equipment was USD 668 million against USD 759 million a year ago. For the nine months, the company reported net sales to third parties from continuing operations of USD 39,105 million against USD 38,480 million a year ago. Net sales of segments from continuing operations were USD 39,289 million against USD 38,650 million a year ago. Operating income from continuing operations were USD 8,738 million against USD 8,650 million a year ago. Income before taxes from continuing operations were USD 9,516 million against USD 8,524 million a year ago. Net income from continuing operations was USD 8,279 million or USD 3.32 per diluted share against USD 7,294 million or USD 2.90 per diluted share a year ago. Total net income attributable to shareholders of the company was USD 8,719 million or USD 3.52 per diluted share against USD 7,146 million or USD 2.88 per diluted share a year ago. Total cash flows from operating activities were USD 8,692 million against USD 8,724 million a year ago. Purchase of property, plant & equipment was USD 1,794 million against USD 1,855 million a year ago. As of September 30, 2014, the net debt stood at USD 9.2 billion compared to USD 8.8 billion at December 31, 2013. The company confirmed its outlook for the year 2014 of low to mid-single digit growth in net sales and core operating income to grow ahead of sales at a mid to high-single digit rate.

FDA Advisory Committee Unanimously Recommends Approval of Novartis's AIN457 (Secukinumab) for Patients with Moderate-To-Severe Plaque Psoriasis

Novartis announced the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the US Food and Drug Administration (FDA) voted 7 to 0 to support the approval of AIN457 (secukinumab), a selective interleukin-17A (IL-17A) inhibitor, for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy (a drug that is absorbed into the bloodstream and distributed to all parts of the body) or phototherapy (light therapy). The DODAC based its recommendation on the safety and efficacy outcomes from 10 psoriasis Phase II/III clinical studies which included nearly 4,000 patients with moderate-to-severe plaque psoriasis.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVS:US $92.69 USD +0.74

NVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $112.00 USD -2.22
Johnson & Johnson $107.78 USD +0.74
Pfizer Inc $29.95 USD +0.11
Roche Holding AG SFr.283.70 CHF +0.30
Procter & Gamble Co/The $87.27 USD +0.33
 

Industry Analysis

NVS

Industry Average

Valuation NVS Industry Range
Price/Earnings 22.3x
Price/Sales 3.7x
Price/Book 3.1x
Price/Cash Flow 23.1x
TEV/Sales 3.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Novartis Ag-adr - NVS news

3 Mega-Cap Dividend Stock Ideas

Quote:
Read article

US doctor pleads guilty in securities case

Keywords: US doctor pleads guilty in securities case, nvs, pe-and-hedgefunds
Quote:
Read article

Awaiting Novartis acquisition, biotech firm Proteon raises $15.2M

Quote:
Read article

Will Investors Regret Leaving The US?

Keywords: ETFs,Investing,Markets,Stocks,Business,Exchange-traded fund,Forbes,IShares,Research and Analysis,Shares outstanding,Trade
Quote:
Read article

LEAD 1-Nestlé porté par la croissance dans les pays émergents

Quote:
Read article

UPDATE 1-Vectura extends VR315 deal with Sandoz to new areas

Keywords: United States, Will Waterman
Quote:
Read article

Momenta's earnings rise on market grab from Sanofi

Quote:
Read article

[$$] Novartis' MS Pill Questioned by U.K. Regulator

Quote:
Read article

9 Swiss Stocks That May Be a Haven

Quote:
Read article

Advisers steer clients to safer havens in stormy market

Keywords: Greece, Italy, Switzerland, RichardSatran, S&P 500
Quote:
Read article

Vanda Pharmaceuticals reports loss

Quote:
Read article

Swiss stocks - Factors to watch on Aug 5

Quote:
Read article

FDA: Generic biotech drugs require paradigm shift

Keywords: Israel, United States, Michele Gershberg, Phil Berlowitz
Quote:
Read article

UPDATE 2-Vectura gets new U.S. partner for copy of lung drug

Keywords: United States, Andrew Callus
Quote:
Read article

UPDATE 1-Vectura strikes new U.S. deal for lung drug VR315

Keywords: United States
Quote:
Read article

UPDATE 1-Finnish drug maker Orion Q2 meets forecast

Keywords: Switzerland, Jane Merriman
Quote:
Read article

Vanda aims for Argentina

Quote:
Read article

Buyout firms to bid for GSK drugs portfolio-sources

Keywords: Britain, Jane Merriman
Quote:
Read article

PDL posts bigger 2Q profit on lower legal costs

Keywords: PDL posts bigger 2Q profit on lower legal costs, nvs,pdli, earnings
Quote:
Read article

Flu "super antibody" may bring universal shot closer

Quote:
Read article
Stocktweeting is not a financial advisor, and in no way recommends the purchase of any stock or advise on the suitability of any trade or investment.
Stock trading and investing can cause loss of capital, and you should always consult with a professional financial advisor before trading or investing.

This website is a service of the HagensMedia ad network. For advertising please visit http://www.hagensmedia.com - Copyright 2011-2012.